Emodin, a natural anthraquinone extracted from the Chinese herbs rhubarb and giant knotweed rhizome, has been reported to enhance osteoblast differentiation. However, the mechanisms underlying its ability to regulate osteogenesis are unclear. The objective of this study was to determine the role of emodin in osteoblast function in vitro and its osteoprotective effect in vivo. Emodin enhanced the differentiation and mineralization of MC3T3-E1 cells, as evidenced by elevated alkaline phosphatase activity and increased number of mineralized nodules. In cultured osteoblasts, emodin significantly induced the mRNA expression of BMP-9 which is one of the least studied but most osteogenic bone morphogenetic proteins (BMPs). Furthermore, the bone morphogenetic protein receptor-Smad (BMPR-Smad) signaling axis and p38 mitogen activated protein kinase (p38 MAPK) were activated. The in vivo function of emodin were evaluated by assessing bone histomorphology, trabecular bone microarchitecture, mechanical properties of the skeleton, and serum parameters of bone turnover in ovariectomized (OVX) rats. Emodin combined with low-dose of estrogen improved trabecular bone microarchitecture in the fourth lumbar vertebra compared with low-dose estrogen alone and enhanced vertebral body strength. Moreover, emodin suppressed the OVX-induced elevation of serum osteocalcin (OC). In addition, there were fewer side effects on uterine hypertrophy with the combination therapy than with high-dose estrogen alone. However, emodin alone did not exert any osteoprotective effect. These results suggest that emodin may be a promising alternative agent for osteoporosis in combination therapy.
Introduction
Osteoporosis is a degenerative disorder characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in fracture risk, and is a major public health threat in our ageing society [1] . Osteoporosis is caused by an imbalance between bone formation and bone resorption. A delicate balance between bone-resorbing osteoclasts and bone-forming osteoblasts is critical for maintaining normal bone mass [2, 3] . Currently, most therapies for osteoporosis, such as anti-resorptive agents (e.g. bisphosphonates, calcitonin, and estrogen), have focused on suppressing excessive osteoclast activity and bone resorption. Although the benefit-to-risk ratio for the treatment with these drugs is strongly positive for most women with osteoporosis, adverse events such as gastrointestinal side effects, the risk of breast and endometrial cancers, and limited cardiovascular benefits have emerged [4] [5] [6] . Hence, it would be helpful to explore natural products, especially those of plant origin, which are considered to be more economical and safer for the treatment of osteoporosis.
Emodin (3-methyl-1, 6, 8-trihydroxyanthraquinone; Fig. 1 ) is one of the active components isolated from the root and rhizome of rhubarb (Rheum palmatum). Pharmacological studies have demonstrated that emodin exhibits a variety of biological activities, such as antiinflammatory, anti-bacterial, anti-tumor, and hepatocyte protective properties [7] [8] [9] . Recent studies have suggested that emodin has a beneficial effect on osteoblast differentiation [10, 11] . However, the underlying molecular mechanism has not been fully examined.
In the present study, we evaluated the osteogenic effects of emodin in vivo and investigated the mechanism underlying emodininduced osteoblast differentiation. The results showed that emodin may exert its osteogenic effects through activation of the BMP-9/ Smad pathway. We further demonstrated that emodin combined with low-dose estrogen effectively ameliorated bone loss and improved bone microarchitecture and bone strength in ovariectomized (OVX) rats. Taken together, our findings reveal that emodin possesses osteoprotective activity and therefore has potential for use in the treatment of osteoporosis caused by estrogen deficiency.
Materials and Methods

Materials
Emodin (HPLC Specification: NLT > 98%) was purchased from Tauto Bio-Technology Co. (Shanghai, China). Dimethyl sulfoxide (DMSO), Alizarin Red S, 17β-oestradiol, GelRed, BCIP/NBT Liquid Substrate System, ascorbic acid, β-glycerophosphate, and sodium carboxymethyl cellulose were purchased from Sigma (St Louis, USA). α-modified minimal essential medium (α-MEM) was purchased from Gibco (Grand Island, USA). Fetal bovine serum (FBS) was purchased from HyClone (Logan, USA). Oligonucleotide primers were synthesized by Takara (Otsu, Japan). PrimeScript RT reagent kit and SYBR Premix Ex Taq were obtained from Takara. A BCA protein assay kit was purchased from Thermo Fisher Scientific (Waltham, USA). A rat-MID osteocalcin (OC) enzyme-linked immunosorbent assay (ELISA) kit and a tartrate-resistant acid phosphatase 5b (TRACP 5b) ELISA kit were purchased from Immunodiagnostic Systems Ltd. (Boldon, UK).
Cell culture and cell treatment
The murine pre-osteoblastic MC3T3-E1 cell line was provided by Prof. Jianjun Gao of the Institute of Radiation Medicine, Fudan University (Shanghai, China). MC3T3-E1 cells were cultured in α-MEM containing 10% FBS and 1% penicillin/streptomycin in a humidified incubator with a 5% CO 2 atmosphere at 37°C.
To ascertain the possible mechanism underlying the anabolic effect of emodin on osteoblasts, cells were pre-treated with 100 ng/ ml Noggin (BMP inhibitor) for 24 h and then cultured in the presence of 0 to 10 μM emodin for 7 days. BMP-9 gene expression was analyzed by quantitative real-time PCR (qRT-PCR), and alkaline phosphatase (ALP) activity was measured.
Cell proliferation assay
Cell proliferation was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyl tetrazolium bromide (MTT) assay. The cells were seeded in 96-well plates at 3 × 10 3 /well with eight wells per group. After treatment with emodin (0-20 μM) for 24, 48, and 72 h, MTT solution (5 mg/ml) was added to each well, and the cells were incubated for 4 h at 37°C. Then, DMSO was added, and the plates were shaken for 5 min to dissolve the formazan products. The absorbance at the test wavelength of 492 nm was measured using a microplate reader (BioTek, Winooski, USA).
ALP activity and staining assay
To measure ALP activity, the cells were seeded into 24-well plates at a density of 2 × 10 4 cells/well (eight wells per group) and incubated for 12 h. Then, the supernatant was removed, and osteogenic medium (α-MEM with 50 mg/ml ascorbic acid, 10 mM b-glycerophosphate, and 100 nM dexamethasone) with 0, 0.05, 0.5, 2.5, 5, or 10 μM emodin was added. The ALP activity assay was performed on the 3rd, 7th, and 14th days of culture. The cells were lysed with 1% Triton X-100, and the lysate was centrifuged at 3000 g for 5 min. Total ALP activity was determined using PNPP as the substrate and DEA as the buffer solution, and the absorbance was measured at 405 nm. Total protein concentration was determined using a BCA protein assay kit. ALP activity was normalized to total protein and expressed as U/mg. For the ALP staining assay, 5 × 10 4 cells/well were seeded into 6-well plates and cultured with osteogenic medium containing 0, 0.05, 0.5, 2.5, 5, or 10 μM emodin for 7 days. The cells were washed twice with PBS solution, fixed with 4% paraformaldehyde for 10 min, rinsed with PBS buffer and incubated with BCIP/NBT alkaline phosphatase liquid substrate.
Mineralization assay
The mineralization assay was performed as previously described [12] [13] [14] . Cells were seeded into 6-well plates at a density of 5 × 10 4 cells/well and cultured in osteogenic medium containing 0, 0.05, 0.5, 2.5, 5, or 10 μM emodin for 21 days. The medium was changed every 3 days. After the cells were harvested, they were fixed in 2.5% glutaraldehyde for 15 min at room temperature and rinsed twice with phosphate-buffered saline (PBS; pH 4.2). Then, the fixed cells were stained with 2% Alizarin Red solution at 37°C for 20 min. After removal of the Alizarin Red solution, the cells were rinsed twice with PBS. Images of Alizarin Red staining were scanned using an Epson Perfection 4990 Photo Scanner (Long Beach, USA).
RNA isolation, RT-PCR, and qRT-PCR
RNA was isolated at specific time points (third and seventh days) after treatment with 0 or 5 μM emodin. The cells were washed twice with PBS, and total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's protocol. To obtain cDNA, quantified RNA was reverse transcribed using PrimeScript™ RT Master Mix (Takara) as described [14, 15] . RT-PCR primer sequences are listed in Table 1 , and the internal standard gene was glyceraldehyde-3-phosphate dehydrogenase (GAPDH). PCR amplification was performed using TaKaRa Ex Taq (Takara) under the following conditions: 30 cycles of 10 s at 98°C, 30 s at 62°C, and 1 min at 72°C. NIH ImageJ software was used to measure the gray intensity values of the target gene bands, which were normalized to GAPDH gene expression in the same sample. qRT-PCR was performed on an ABI 7500 System (Applied Biosystems, Foster City, USA) using the SYBR Green Premix Ex Taq™ Kit (Takara).
qRT-PCR primer sequences are listed in Table 2 , mouse GAPDH was used as the internal control to normalize gene expression. The fold change in expression was calculated using the ΔΔCt comparative threshold cycle method.
Construction of recombinant adenoviruses expressing BMP-9 and GFP
Recombinant adenoviruses expressing BMP-9 were constructed using AdEasy technology as previously described [14, 16] . In brief, the coding region of human BMP-9 was PCR amplified and cloned into an adenoviral shuttle vector that was subsequently used to generate recombinant adenoviruses (designated AdBMP9) in HEK293 cells. AdBMP9 also expressed GFP, which was used to monitor the infection efficiency. Analogous adenovirus expressing only monomeric GFP (AdGFP) was used as a control [12, 13, 15, 17, 18] . To enhance the adenoviral infection efficiency, Polybrene (4 mg/ml) was added to the medium [19] .
Transfection and luciferase reporter assay
The reporter plasmid p12 × SBE-Luc were generated as described previously [20] . The plasmid contains 12 copies of Smad1 binding element (12 × SBE). When the BMP/Smad signaling is activated, the luciferase activity can be stimulated and measured [15, 20] . Exponentially growing cells were seeded in 25 cm 2 cell culture flasks and transfected with 2 mg p12 × SBE-Luc per flask using Lipofectamine transfection reagent (Invitrogen) as previously described [13, 15, 18] . After transfection, cells were treated with AdBMP9, emodin (5 μM) or DMSO. After 36 h, 20 μl of the 100-μl cell extract was analyzed by luciferase assay using a Dual-Luciferase Kit (Promega, Madison, USA). Transfection efficiency was normalized to Renilla luciferase activity.
Western blot analysis
Western blot assay was performed on the seventh day of culture after treatment with 0 or 5 μM emodin. 
Bio-Rad, Hercules, USA). GAPDH was used as the internal control for protein loading.
Animal grouping and treatments
Sprague-Dawley (SD) rats were obtained from the Experimental Animal Center, Second Military Medical University (Shanghai, China). The rats were housed in an air-conditioned room at 23°C-25°C with a 12 h light/dark cycle, and the rats had free access to food pellets and water. All the animal experiments were approved by the Ethics Committee of Xinhua Hospital, Shanghai Jiaotong University School of Medicine (Approval No. XHEC-F-2014-002). All the experimental procedures were performed in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals. In total, 60 twelve-week-old female Sprague-Dawley rats weighing 250-300 g were randomly assigned into six equal groups of 10 rats as follows: Sham operated + vehicle (0.9% sodium carboxymethyl cellulose), OVX + vehicle, OVX + 500 μg/kg/day 17β-oestradiol (E 2 -H), OVX + 50 μg/kg/day 17β-oestradiol (E 2 -L), OVX + 100 mg/kg/day emodin (Emodin), OVX + 50 μg/kg/day 17β-oestradiol + 100 mg/kg/day emodin (E 2 -L + Emodin). The concentrations of 17β-oestradiol were chosen according to a previous study [21] . The various treatments began at 1 week after surgery and continued for 12 weeks. After 12 weeks of treatment, the animals were euthanized by an i.p. injection of 100 mg/ kg ketamine combined with 10 mg/kg diazepam, and blood was collected from the aorta abdominalis. After the blood was centrifuged at 3,000 g for 10 min, the serum was harvested and stored at −80°C until analysis. The uteri were removed and immediately weighed. The L3 vertebra and femur were stored at −20°C until examination for bone biomechanical quality, and the L4 vertebra was dissected and placed in bottles with 75% ethanol.
Serum parameters
The serum concentrations of the bone formation marker OC and the bone resorption marker tartrate-resistant acid phosphatase form 5b (TRACP 5b) were determined using ELISA kits according to the manufacturer's protocol.
Bone histology
The right tibiae were prepared for bone histomorphology analysis. The tibiae were dissected, fixed with 4% paraformaldehyde at 4°C for 48 h, and then decalcified in 10% EDTA. After decalcification for 4 weeks, the bones were dehydrated with increasing concentrations of ethanol, cleared in xylene, and embedded in paraffin. Serial 4-μm sagittal sections of the tibiae were cut with a Leica microtome (Leica RM 2135; Leica, Wetzlar, Germany) and placed on slides for haematoxylin and eosin staining. Sections were examined using a photomicroscope suite (Olympus DP71; Olympus, Tokyo, Japan).
Micro-CT imaging analysis
The trabecular microarchitecture of the L4 vertebra was measured using a microcomputed tomography (Micro-CT) system (eXplore Locus SP Pre-Clinical Specimen; GE Healthcare, Madison, USA). The vertebra was scanned from the anterior endplate to the posterior endplate with an isotropic resolution of 15 μm, and images were reconstructed to an isotropic voxel size of 30 μm. The volume of interest (VOI) was selected at a region five slices away from the anterior endplate to the posterior endplate. The 3D images were obtained from the system software (MicroView, v.2.1), and the bone morphometric parameters of bone volume over total volume (BV/TV), trabecula number (Tb.N), trabecula separation (Tb.Sp), connectivity density (Conn.D), and bone mineral density (BMD) were determined by analyzing the VOI.
Mechanical evaluation
To evaluate bone strength, the left femur and L3 vertebra were subject to a three-point bending and axial compression test using a materials testing machine (Instron 5543; Instron, Norwood, USA). Briefly, femurs were placed on two supports spaced 18 mm apart, subjected to a pre-load of 1 N on the surface at mid-shaft at a speed of 0.1 mm/min as contact force, and then deformed at a rate of 10 mm/min until failure. The load-deformation curve was plotted and analyzed using Instron Merlin software (version 4.03). The force and displacement data were automatically recorded until the sample was broken. Bone biomechanical parameters, including ultimate load (N), ultimate stress (MPa), and Young's modulus (MPa), were obtained by analyzing the load-deformation curve.
Statistical analysis
The data are presented as the mean ± standard deviation (SD). Oneway analysis of variance followed by Dunnett's test or Student's t-test was performed for statistical analysis (SPSS version 13.0). P < 0.05 was considered to indicate statistical significance.
Results
Emodin has no effect on MC3T3-E1 cell proliferation
Before evaluating the effect of emodin on the oateoblast differentiation and mineralization, its effect on the cell proliferation was determined by MTT assay. As shown in Fig. 2 , the absorbance at the test wavelength of 492 nm was decreased in the presence of emodin at concentrations of 20 μM, whereas there were no significant differences among the control group and emodin-treated groups at concentration of 0-10 μM. These results imply that emodin at lowdose has no effect on MC3T3-E1 proliferation.
Emodin stimulates the differentiation and mineralization of MC3T3-E1 cells
To determine whether emodin has effect on osteoblast differentiation, the ALP assay was performed. The effect of emodin on ALP Figure 2 . Emodin has no effect on MC3T3-E1 cell proliferation Cells were treated with 0.05 to 20 μM emodin for 24, 48, or 72 h. *P < 0.05 compared with the control group (0 μM).
activity in MC3T3-E1 cells was examined on Days 3, 7, and 14 of culture. The quantitative assay showed that ALP activity was increased in the presence of emodin at concentrations up to 10 μM at all time points examined (Fig. 3A-C) . Compared with untreated time-matched controls, 5 μM emodin significantly stimulated ALP activity by 2.5-, 3.0-, and 1.7-fold on Days 3, 7, and 14, respectively. The ALP histochemical staining results on Day 7 were consistent with the quantitative ALP activity assay results (Fig. 3D) . The effect of emodin on the mineralization of MC3T3-E1 cells was examined by Alizarin Red staining. After continuous treatment for 21 days, the number of mineralized nodules was significantly increased in the presence of 0.5, 2.5, and 5 μM emodin, with a maximal effect at 5 μM (Fig. 4) . These findings demonstrate that emodin stimulates the differentiation and mineralization of MC3T3-E1 cells.
Emodin promotes marker gene expression in osteogenesis
To examine the specific signaling pathways involved in emodininduced osteoblast differentiation, the expression levels of osteogenic markers were assessed by RT-PCR (Fig. 5A ). As shown in Fig. 5B , the qRT-PCR results showed that BMP-9, ALK1, Smad1, Smad9, Msx2, and Osterix mRNA expression was up-regulated on Days 3 and 7 in response to 5 μM emodin. The effect of emodin on BMP-9 expression was particularly remarkable, with a 3-fold increase compared with the untreated control at Day 7 (Fig. 5B) . However, the RT-PCR results showed that p38, ERK1, JNK mRNA which are related to MAPK signaling pathway were not up-regulated by emodin (Fig. 5A) .
Emodin activates the BMPR-Smad pathway
qRT-PCR analysis results showed that emodin significantly upregulated BMP-9 expression (P < 0.05; Fig. 5B ). Then the effect of emodin on Smad signaling was further examined. The BMPR-Smad reporter p12 × SBE-Luc contains Smad1 responsive elements. When the BMPR-Smad signaling is activated, the luciferase activity can be stimulated and measured. Therefore, the BMPR-Smad reporter p12 × SBE-Luc was transfected into MC3T3-E1 cells, and the infection efficiency was shown in Fig. 6A . The results showed that emodin enhanced the reporter activity by approximately 3.0-fold (P < 0.05) (Fig. 6B) . These results suggest that emodin may exert osteogenesis effect at least in part through up-regulation of BMP-9 expression and activation of BMPR-Smad signaling axis.
Smad1/5/8 and p38 MAPK are activated in emodininduced osteoblast differentiation
To test the hypothesis that Smad1/5/8 and p38 MAPK signaling pathways are essential for emodin-induced osteoblast differentiation, we determined whether Smad1/5/8 and MAPKs were activated in M3C3T3-E1 cells in response to emodin stimulation. Western blot analysis was used to determine activation-associated phosphorylation of p38 MAPK and Smad1/5/8 using phosphospecific antibodies. It was found that after emodin treatment, there was a significant increase in Smad1/5/8 and p38 phosphorylation, whereas the total Smad1/5/8 and p38 MAPK protein levels did not change (Fig. 7) , indicating that Smad1/5/8 and p38 MAPK are activated in emodin-induced osteoblast differentiation.
Emodin-induced osteoblast differentiation can be blocked by noggin
To further determine the role of BMP-9 in emodin-induced osteoblast differentiation, we investigated the effects of signaling inhibitors on ALP activity in MC3T3-E1 cells. Pretreatment with the BMP inhibitor, noggin, significantly inhibited the expression of BMP-9 ( Fig. 8A) and reduced emodin-induced ALP activity compared with controls (Fig. 8B) . In particular, the ALP activity of cells co-treated with noggin and 5 μM emodin for 7 days was reduced by 70%. These results further indicate that the emodin-mediated enhancement of osteoblast differentiation occurs primarily through upregulation of BMP-9 expression.
Emodin has no effect on uterine weight in OVX rats
As shown in Fig. 9 , the uterine weight was significantly decreased in OVX rats compared with that in the sham group (P < 0.05). The E 2 -H group showed a significantly increased uterine wet weight compared with the OVX group (P < 0.05). The uterine weight of the E 2 -L group was significantly decreased compared with that of the E 2 -H group (P < 0.05), and there was no significant difference between the E 2 -L + Emodin group and E 2 -L group, demonstrating that emodin does not promote hypertrophy of the uterus.
Emodin suppresses OVX-induced bone turnover
To evaluate the effect of emodin on the serum biochemical markers of bone turnover, we determined serum concentrations of OC and TRACP 5b. As shown in Fig. 10A , serum OC levels were increased in the OVX group compared with the sham group (P < 0.05). Serum OC levels were decreased by 26.4% and 35.8% in the E 2 -H and E 2 -L + Emodin groups, respectively, compared with the OVX group (P < 0.05). However, no significant difference was observed among the Emodin, E 2 -L and OVX groups. Compared with the sham group, serum TRACP 5b was decreased by 42.0% in the OVX group (P < 0.05). However, there were no significant differences among the treatment groups (Fig. 10B) . These findings indicate emodin can synergize with low-dose estrogen to suppress OVXinduced bone turnover.
Emodin prevents OVX-induced trabecular bone loss in vivo
The sections of the tibiae were examined for the histological changes. The animals in the sham group showed normal compactness of the diaphysis and competent trabeculae (Fig. 11A) . OVX led to a reduced amount of trabecular bone (Fig. 11B) . Emodin combined with low-dose E 2 effectively maintained normal morphology at the proximal tibia compared with OVX alone and was more effective than E 2 -H (Fig. 11F) . These results show that emodin and low-dose estrogen synergistically improve OVX-induced trabecular bone loss.
Emodin ameliorates the OVX-mediated deterioration in the trabecular microarchitecture
Three-dimensional reconstruction of trabecular bone from the fourth lumbar vertebra is shown in Fig. 12 . Quantitative data on architectural parameters are presented in Table 3 . As expected, deterioration of the trabecular architecture was observed in the OVX group, evidenced by significant reductions in BV/TV, Tb.N, and Conn.D, and increase in Tb.Sp compared with the sham group (P < 0.05). Compared with the OVX group, E 2 -L + Emodin increased BV/TV, Tb.N, and Conn.D by 12.4%, 55.6%, and 47.3%, respectively, and decreased Tb.Sp by 22.2%. However, no significant differences were observed among the Emodin, E 2 -L and OVX groups. Furthermore, the E 2 -L + Emodin group showed an increased BMD compared with the OVX group. These results show that emodin and low-dose estrogen synergistically improve OVXinduced deterioration of trabecular bone.
Emodin improves the biomechanical strength of bone in OVX rats
The data on the biomechanical parameters of each group are shown in Table 4 . Compared with the sham group, the biomechanical parameters of the vertebral body, such as the ultimate load, ultimate stress, and Young's modulus, were lower in the OVX group (P < 0.05). Treatment with E 2 -L + Emodin prevented the OVX-induced decreases in the biomechanical parameters (P < 0.05). No significant differences were observed among the OVX, E 2 -L, and Emodin alone groups. Treatment with emodin or E 2 was unable to improve the biomechanical parameters of the femur. These data reveal that emodin improves strength properties in OVX rats when combined with low-dose estrogen.
Discussion
In our previous experiment, we have observed that emodin can promote differentiation of preosteoblasts at concentrations of 0-5 μM and the expression of BMP-9 is remarkably up-regulated [22] . However, the molecular mechanism has not been intensively studied and the in vivo effects of emodin are still not clear. In this study, the OVX rat model was established to simulate postmenopausal osteoporosis and the in vivo effects of emodin were determined. We demonstrated that treatment with emodin or low-dose 17β-oestradiol individually was not effective against osteoporotic bone loss in OVX rats. However, when the two drugs were combined, the OVX-induced reductions in trabecular bone volume and connectivity were mitigated, and the uterine weight of the OVX rats was not increased. Furthermore, the in vitro results showed that emodin may exert its osteogenic effects at least in part through activation of the BMP-9/Smad signaling axis. The osteogenic effect of emodin has been gradually recognized. Low concentrations of emodin accelerate osteoblastic differentiation by inducing BMP-2 expression in vitro [10] . A more recent study showed that emodin enhances osteogenesis and inhibits adipogenesis in BMSCs [11] . Nonetheless, the molecular mechanism underlying osteogenesis is not entirely clear. In our study, emodin was found to increase the ALP activity and mineralization of MC3T3-E1 cells at low concentrations without affecting cell proliferation, which is in accordance with the findings of a previously study [10] . Additionally, our study is the first to show that emodin may exert osteogenic effects at least in part through up-regulating BMP-9 expression and activating the BMPR-Smad signaling axis.
Bone homeostasis is delicately regulated by various signaling pathways, including the notable bone morphogenetic protein (BMP), Wnt, Notch, and MAPK paracrine signaling pathways [23] . Our results showed that BMP-9 mRNA expression was significantly higher in emodin-treated cells compared with control cells, and BMP-9 levels were higher than BMP-2 levels (Fig. 5) , and western blot analysis showed that emodin up-regulated the BMP-9 expression (Fig. 7) . The BMP family contains some of the most potent osteogenic growth factors and possesses the capability to promote osteogenesis and chondrogenesis [24] . Within the BMP family, BMP-9 is more potent at inducing the osteogenic differentiation of stem cells than other BMPs, such as BMP-2 and BMP-7 [25, 26] . Although BMP-9 is one of the least investigated BMPs, the potent osteogenic activity of BMP-9 suggests it may be used as an efficacious bone-regeneration agent. A previous study showed that Smad1/5/8, p38 and ERK1/2 are involved in the BMP9-induced osteogenic differentiation of MSCs, but p38 and ERK1/2 MAPK act in opposition to regulate the BMP9-induced osteogenic differentiation of MPCs [27] . Furthermore, the p38 and ERK1/2 MAPK pathways have opposite effects on BMP9-induced PDLSC differentiation [28] . The differences in signaling pathways modulated by BMP-9 may depend on the species of the cell line and the developmental stage of the target cells. Our study showed that the mRNA levels of p38, ERK1, and JNK, which are related to the MAPK signaling pathway, were not up-regulated by emodin (Fig. 5A) , but western blot analysis showed that emodin increased the phosphorylation of p38. Our study also indicated that the mRNA expression of ALK1, Smad1, and Smad9 was increased at Day 7 of culture, which is in accordance with the change in BMP-9 gene expression at the same time point. ALK1 was identified as a potential receptor for BMP-9 that is responsible for BMP-9 osteogenic signaling [17, 29] . Xu et al. [30] demonstrated that BMP-9 promotes the activation of Smad1/5/8 and that Smad signaling is required for the BMP-9-induced osteogenic differentiation of MSCs. Moreover, in our study, the expression of Msx2 and osterix, which have long been recognized as osteogenesis-specific transcription factors, was found to be simultaneously increased (Fig. 5 ) [31] . It was also found that emodin enhanced BMPR-Smad reporter activity. Furthermore, western blot assay showed that emodin enhanced the phosphorylation of Smad1/5/8. Collectively, these results suggest that emodin may exert osteogenic effects at least in part by upregulating BMP-9 expression and activating the BMPR-Smad signaling axis, and the p38 MAPK is involved in the process of emodin-induced osteogenic differentiation of MC3T3-E1 cells. Nonetheless, the molecular mechanism underlying the activation of BMP-9 expression requires further investigation. Figure 9 . Emodin has no effect on uterine weight in OVX rats Female SD rats were randomly assigned into the following groups: Sham, sham operated; OVX, OVX treated with vehicle; E 2 -H, OVX + 500 μg/kg/day 17β-estradiol; E 2 -L, OVX + 50 μg/kg/day 17β-estradiol; Emodin, OVX + 100 mg/kg/day emodin; and Emodin + E 2 -L, OVX + 100 mg/kg/day emodin + 50 μg/kg/day 17β-estradiol. *P < 0.05 compared with the OVX group. Figure 10 . Emodin suppresses OVX-induced bone turnover Female SD rats were randomly assigned into the following groups: Sham, sham operated; OVX, OVX treated with vehicle; E 2 -H, OVX + 500 μg/kg/day 17β-estradiol; E 2 -L, OVX + 50 μg/kg/day 17β-estradiol; Emodin, OVX + 100 mg/kg/day emodin; and Emodin + E 2 -L, OVX + 100 mg/kg/day emodin + 50 μg/kg/day 17β-estradiol. *P < 0.05 compared with the OVX group. Figure 11 . HE-stained histological sections of tibia Female SD rats were randomly assigned into the following groups: (A) sham operated (Sham), (B) OVX treated with vehicle (OVX), (C) OVX + 500 μg/kg/day 17β-estradiol (E 2 -H), (D) OVX + 50 μg/kg/day 17β-estradiol (E 2 -L), (E) OVX + 100 mg/kg/day emodin (Emodin), and (F) OVX + 100 mg/kg/day emodin + 50 μg/kg/day 17β-estradiol (Emodin + E 2 -L). The sham group showed uniform, integrated trabeculae with normal connectivity, whereas the OVX, E 2 -L, and Emodin groups showed sparse, thin trabeculae with wide inter-trabecular spaces. The Emodin + E 2 -L group showed thick trabeculae and the restoration of normal architecture. Figure 12 . Three-dimensional reconstruction of trabecular bone from the fourth lumbar vertebra (A) Sham operated (Sham), (B) OVX treated with vehicle (OVX), (C) OVX + 500 μg/kg/day 17β-estradiol (E 2 -H), (D) OVX + 50 μg/ kg/day 17β-estradiol (E 2 -L), (E) OVX + 100 mg/kg/day emodin (Emodin), and (F) OVX + 100 mg/kg/day emodin + 50 μg/kg/day 17β-estradiol (Emodin + E 2 -L).
An imbalance between bone resorption and formation will result in the loss of bone mass and deterioration of trabecular bone microarchitecture. Although the use of anti-resorptives such as estrogens can reduce the rate of bone loss, this strategy has many drawbacks, such as increased risks of cancer and cardiovascular disease [32, 33] , and the effects are not sufficient to restore BMD to premenopausal levels [34] . If a new type of drug could exert effects on bone formation in combination with estrogen, it could diminish the side effects of estrogen, and the efficacy should be far greater than that achieved with anti-resorptives. As the above results strongly suggest that emodin exerts an osteogenic effect in vitro, we hypothesize that emodin may be an effective skeletal anabolic agent in OVX rats. However, whether emodin alone or in combination with estrogen exerts an osteoprotective effect in OVX rats needs to be further explored.
Our results revealed that emodin reduced bone loss in OVX rats when combined with low-dose estrogen compared with low-dose estrogen alone. To observe the histological changes in bone tissue, the right tibiae was prepared for bone histomorphology analysis. The sham and OVX + Emodin + E 2 -L groups showed thick, uniform trabeculae with normal connectivity, while the OVX + Vehicle, OVX + E 2 -L, and OVX + Emodin groups showed sparse, thin trabeculae with wide inter-trabecular spaces. The L4 vertebrae of rats in each group were scanned by micro-CT to quantify the microarchitectural properties of bone tissue. The results showed a complete restoration of trabecular bone by the combination of emodin and low-dose estrogen. Consistent with the micro-architectural analysis, the L3 vertebrae of Emodin + E 2 -L group exhibited better strength properties compared with the OVX and E 2 -L groups. In addition, serum OC levels were significantly higher in the OVX group than in the sham group, whereas Emodin + E 2 -L administration prevented the increase in serum OC. Serum OC is presently considered as a valid marker of bone turnover. Elevated serum OC levels have been found during periods of rapid bone turnover, such as osteoporosis, multiple myeloma, and fracture repair. Therefore, we consider that emodin and low-dose estrogen synergistically suppresses OVX-induced bone turnover [35] . Recent studies have shown that secreted TRACP 5b is indicative of the number of osteoclasts rather than their activity, and these values are expected to decrease after OVX [36] . In this study, a bone resorption marker TRACP 5b activity was found to be decreased after OVX, and Emodin + E2-L was unable to prevent this decrease.
OVX resulted in pronounced atrophy of the uterus, which could be prevented by E 2 treatment. The uterine weight in E 2 -H group was not significantly different from that in the sham group, which indicated that 500 μg/kg/day 17β-estradiol could promote endometrial hypertrophy in OVX rats. This hypertrophy could be one of the most important mechanisms for the estrogen-induced increase in the risk of uterine bleeding and endometrial cancer. However, the uteri in the OVX rats treated with emodin and low-dose estrogen were atrophied, with no significant difference compared with the OVX group, indicating that emodin does not promote hypertrophy of the uterus. These findings may suggest that the combination treatment can diminish the uterine complications caused by common-dose estrogen.
The significant difference between the combination group and the low-dose estrogen-alone group indicated that emodin and low-dose estrogen synergistically suppressed OVX-induced bone turnover.
In conclusion, our results suggest that emodin promotes osteoblast differentiation and mineralization at least in part by upregulating BMP-9 expression and activating the BMPR-Smad signaling axis, and the p38 MAPK may involve in the emodin-induced osteogenesis process. Moreover, emodin can synergize with lowdose estrogen to improve the quality of bone tissues in OVX rats. In addition, the combination therapy causes few side effects on uterine hypertrophy and is therefore beneficial in reducing the adverse effects of E 2 treatment. Therefore, the combination of emodin and low-dose estrogen may be a better choice for preventing postmenopausal osteoporosis. Data are expressed as the mean ± SD. n = 10 in each group. *P < 0.05 compared with the OVX group, and # P < 0.05 compared with the E 2 -L group. Data are expressed as the mean ± SD. n = 10 in each group. *P < 0.05 compared with the OVX group, and # P < 0.05 compared with the E 2 -L group.
